Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ779550B2 - Multivalent pd-l1 binding compounds for treating cancer - Google Patents
[go: Go Back, main page]

NZ779550B2 - Multivalent pd-l1 binding compounds for treating cancer - Google Patents

Multivalent pd-l1 binding compounds for treating cancer Download PDF

Info

Publication number
NZ779550B2
NZ779550B2 NZ779550A NZ77955020A NZ779550B2 NZ 779550 B2 NZ779550 B2 NZ 779550B2 NZ 779550 A NZ779550 A NZ 779550A NZ 77955020 A NZ77955020 A NZ 77955020A NZ 779550 B2 NZ779550 B2 NZ 779550B2
Authority
NZ
New Zealand
Prior art keywords
polypeptide
multivalent
cell death
ligand
programmed cell
Prior art date
Application number
NZ779550A
Other versions
NZ779550A (en
Inventor
Michael A Barry
Original Assignee
Mayo Foundation For Medical Education And Research
Filing date
Publication date
Application filed by Mayo Foundation For Medical Education And Research filed Critical Mayo Foundation For Medical Education And Research
Priority claimed from PCT/US2020/030240 external-priority patent/WO2020223217A1/en
Publication of NZ779550A publication Critical patent/NZ779550A/en
Publication of NZ779550B2 publication Critical patent/NZ779550B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

This invention provides methods and materials for treating cancer. The invention encompasses methods and materials for delivering programmed death-ligand 1 (PD-L1) binding compounds and/or compositions containing one or more monovalent or multivalent programmed death-ligand 1 (PD-L1) binding compounds which are administered to a mammal having cancer to treat the mammal. In some cases, a multivalent PD-L1 binding compound can include two or more programmed cell death protein 1 (PD-1) polypeptides (and/or fragments thereof having the ability to bind PD-L1). This invention also provides methods and materials for making multivalent PD-L1 binding compounds and methods and materials for making nucleic acid molecules that encode PD-L1 binding compounds.

Claims (12)

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1. A multivalent programmed cell death protein ligand 1 (PD-L1) binding compound, comprising a plurality of amino acid chains, wherein each amino acid chain comprises at least one programmed cell death n 1 (PD-1) polypeptide, wherein each amino acid chain sing at least one programmed cell death protein 1 (PD-1) polypeptide is associated with a recombinant Adenovirus (Ad) and the plurality of amino acid chains are present on a coat polypeptide of the recombinant Ad, and n the recombinant Ad comprises capsid hexon polypeptides of an Ad strain Ad6 and at least one capsid hexon hypervariable region (HVR) polypeptide from Ad strain Ad57.
2. The multivalent programmed cell death protein ligand 1 (PD-L1) binding nd of claim 1, wherein the capsid hexon polypeptides of an Ad strain Ad6 comprise HVR polypeptides 1-7 from Ad strain Ad57.
3. The multivalent programmed cell death protein ligand 1 (PD-L1) binding compound of claim 1, n the capsid hexon polypeptides of an Ad strain Ad6 comprise HVR polypeptides 2-6 from Ad strain Ad57.
4. The multivalent programmed cell death protein ligand 1 (PD-L1) binding compound of any one of claims 1 to 3, wherein the programmed cell death protein 1 (PD-1) polypeptide is a human PD-1 or a murine PD-1.
5. The multivalent programmed cell death protein ligand 1 (PD-L1) g compound of any one of claims 1 to 4, wherein the recombinant Ad is r modified to se heterologous polypeptides selected from targeting polypeptides, therapeutic polypeptides and antigens.
6. The multivalent mmed cell death protein ligand 1 (PD-L1) binding compound of claim 5, wherein the targeting polypeptide is selected from a measles virus lutinin (MVH) polypeptide, a measles virus fusion (MVF) polypeptide, and a vesicular stomatitis virus glycoprotein (VSVG) polypeptide.
7. The multivalent programmed cell death protein ligand 1 (PD-L1) binding compound of claim 5, wherein the therapeutic polypeptide is selected from a 4-1BB ligand (4-1BBL) polypeptide, a OX40 ligand ) ptide, a CD40 ligand (CD40L) polypeptide, and a granulocyte-macrophage colony-stimulating factor (GMCSF ) polypeptide.
8. The multivalent programmed cell death protein ligand 1 ) binding compound of any one of claims 1 to 7, wherein the PD-1 polypeptide is fused to a n K-dependent gamma-carboxyglutamic domain of a factor X single-chain antibody polypeptide (a GLA domain of an FX polypeptide).
9. The multivalent programmed cell death protein ligand 1 ) binding compound of any one of claims 1 to 8, wherein each amino acid chain comprises a targeting molecule selected from a measles virus hemagglutinin (MVH) polypeptide, a measles virus fusion (MVF) ptide, and a vesicular stomatitis virus glycoprotein (VSVG) polypeptide.
10. The multivalent programmed cell death protein ligand 1 (PD-L1) binding compound of claims 1 to 9, wherein each amino acid chain comprises one or more therapeutic polypeptides selected from a 4-1BB ligand (4-1BBL) polypeptide, a OX40 ligand (OX40L) polypeptide, a CD40 ligand (CD40L) polypeptide, and a granulocytemacrophage colony-stimulating factor (GM-CSF) polypeptide.
11. A ceutical composition comprising the multivalent programmed cell death protein ligand 1 (PD-L1) binding compound of any one of claims 1 to 10 and a pharmaceutically acceptable carrier.
12. Use of a nd or pharmaceutical composition as claimed in any one of claims 1 to 11 in the preparation of a medicament for use in treating cancer in a subject in need thereof.
NZ779550A 2020-04-28 Multivalent pd-l1 binding compounds for treating cancer NZ779550B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962839916P 2019-04-29 2019-04-29
PCT/US2020/030240 WO2020223217A1 (en) 2019-04-29 2020-04-28 Multivalent pd-l1 binding compounds for treating cancer

Publications (2)

Publication Number Publication Date
NZ779550A NZ779550A (en) 2024-08-30
NZ779550B2 true NZ779550B2 (en) 2024-12-03

Family

ID=

Similar Documents

Publication Publication Date Title
US11096989B2 (en) Synergistic tumor treatment with an extended pharmacokinetic IL-2 and integrin-binding-Fc fusion protein
KR20220101147A (en) Activatable cytokine polypeptides and methods of use thereof
JP6023703B2 (en) Fibronectin based scaffold proteins with improved stability
CN114317461A (en) Adenoviruses expressing immune cell stimulating receptor agonists
TWI500629B (en) Antibodies to interleukin-6 and uses thereof
US20240216505A1 (en) Inducible cytokine prodrug and pd-1/pd-l1 combination therapy
KR102729109B1 (en) Multivalent PD-L1 binding compounds for the treatment of cancer
TW202309072A (en) Oncolytic viruses encoding recombinant tranforming growth factor (tgf)-beta monomers and uses thereof
NZ779550B2 (en) Multivalent pd-l1 binding compounds for treating cancer
US20260103541A1 (en) Paracrine Adenoviral Delivery of Biomolecules
US20230293688A1 (en) Fusogenic rhabdovirus glycoproteins and uses thereof
RU2021133870A (en) MULTIVALENT PD-L1 BINDING COMPOUNDS FOR THE TREATMENT OF MALIGNANT NEOPLASMS
CN117693350A (en) Combination of checkpoint inhibitors and oncolytic viruses for cancer treatment
RU2816646C2 (en) Multivalent pd-l1-binding compounds for treating malignant neoplasms
KR20260010769A (en) Pharmaceutical composition containing virus particles and method of using the same
WO2025061682A1 (en) Adenoviral targeting of dendritic cells
HK40062457A (en) Multivalent pd-l1 binding compounds for treating cancer
WO2025188938A1 (en) Engineered cells and methods of using the same
EP4581055A1 (en) Adenoviral-based in situ delivery of bispecific t cell engagers
CN120441708A (en) A bispecific antibody targeting CD3 and L1CAM and its application
US20180105802A1 (en) Viral Targeting with Knottins
HK1230236A1 (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)